Skip to main content
Medical information Clinical review pending

Cytogenetics

Del7q MDS

The Del7q MDS test detects chromosomal abnormalities associated with myelodysplastic syndromes (MDS), aiding in diagnosis and treatment planning. Confirm with the laboratory before booking.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Bone marrow aspirate or peripheral blood sample. Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No specific patient preparation is required. However, a doctor's prescription is necessary. Confirm with the laboratory before booking.
Test priceKSh 10,500

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Del7q MDS test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Patients with symptoms suggestive of MDS (e.g., fatigue, weakness, frequent infections).
  • ✓Individuals with unexplained abnormalities in blood counts.
  • ✓Patients undergoing evaluation for blood disorders.
  • ✓Monitoring disease progression in known MDS patients.
  • ✓Guiding treatment decisions based on genetic findings.
02

In plain language

What this test helps you understand

This test helps in the diagnosis, prognosis, and treatment planning for patients suspected of having myelodysplastic syndromes (MDS). It identifies specific chromosomal abnormalities (deletion on chromosome 7q) associated with MDS.
The Del7q MDS test is a specialized diagnostic procedure used to identify specific chromosomal abnormalities linked to myelodysplastic syndromes (MDS). MDS is a group of conditions where the bone marrow does not produce enough healthy blood cells. This test helps healthcare providers understand the specific genetic changes driving the disease in an individual, which can influence treatment choices and prognosis.

This test uses Fluorescence In Situ Hybridization (FISH) technology to examine cells from a bone marrow or peripheral blood sample. It specifically looks for deletions (missing parts) on the long arm (q) of chromosome 7. Identifying this deletion can provide important information about the type and potential severity of MDS.

Understanding the results of the Del7q MDS test is crucial for effective management of MDS. Discuss your results thoroughly with your doctor to understand their implications for your health and treatment plan.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo specific patient preparation is required. However, a doctor's prescription is necessary. Confirm with the laboratory before booking.
SampleBone marrow aspirate or peripheral blood sample. Confirm specific requirements with the laboratory before booking.
MethodologyFluorescence In Situ Hybridization (FISH).
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects only the specific deletion on chromosome 7q. It does not detect other chromosomal abnormalities or genetic mutations associated with MDS. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Myelodysplastic syndromes (MDS) are a group of disorders caused by problems in the bone marrow, leading to the production of poorly formed or dysfunctional blood cells.
This test detects a specific chromosomal abnormality called a deletion on the long arm (q) of chromosome 7, which is associated with certain types of MDS.
Identifying the Del7q abnormality can help doctors diagnose MDS, understand its potential severity, and make informed decisions about treatment options.
No specific fasting is required for this test. However, a doctor's prescription is needed.
A healthcare professional will interpret the results in the context of your overall health status, blood tests, and other clinical findings. Discuss your results with your doctor.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp